Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Complejo Hospitalario Universitario de Vigo | OTHER |
Not provided
Not provided
Not provided
Not provided
Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib.
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Unic group | Patients diagnosed with NSCLC undergoing treatment with osimertinib in the Vigo Health Area, who receive pharmaceutical care in the Outpatient Clinics of the Pharmacy Service of the Álvaro Cunqueiro Hospital. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Unic group | Other | To describe the nutritional status and body composition of patients diagnosed with non-melanoma skin cancer (NMSC) treated with osimertinib in the Vigo health area. To evaluate the prevalence of sarcopenia in the study patients. To observe if there is a relationship between low muscle mass or malnutrition and the development of delayed-type hyperplasia (DTH) during osimertinib treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Gender | Patient gender (Female, Male) | Day 0, During the consultation |
| Age | Patient age in years | Day 0, During the consultation |
| Stage of NSCLC | Non-Small Cell Lung Cancer (NSCLC) is staged from 0 to IV based on tumor size (T), lymph node involvement (N), and metastasis (M). | Day 0, During the consultation |
| Start date of Osimertinib treatment | Date of initiation of osimertinib therapy as recorded in the medical record. | Day 0, During the consultation |
| Initial and current osimertinib dose | Dose of osimertinib in milligrams (mg/day) at treatment initiation and at the time of assessment. | Day 0, During the consultation |
| Total duration of osimertinib treatment | Total duration of osimertinib therapy calculated from treatment initiation to discontinuation or last follow-up, expressed in days. | Day 0, During the consultation |
| Dose-limiting toxicities (DLTs) | Incidence and type of dose-limiting toxicities experienced during osimertinib treatment, graded according to CTCAE criteria. The most common DLTs included diarrhea, mucositis, folliculitis, nausea, thrombocytopenia, paronychia, and elevated transaminases. | Day 0, During the consultation |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnosis of malnutrition | Following GLIM criteria (Global Leadership Initiative on Malnutrition): Phenotypic Criteria:
The combination of at least one phenotypic criterion and one etiological criterion enabled the diagnosis of malnutrition. The etiological criterion of inflammation, required for the diagnosis of malnutrition, was met in all study patients as they were diagnosed with NSCLC. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Withdrawal criteria:
- Revocation of consent to participate in the study by the patient.
Not provided
Not provided
Not provided
Patients diagnosed with NSCLC undergoing treatment with osimertinib in the Vigo Health Area, who receive pharmaceutical care in the Outpatient Clinics of the Pharmacy Service of the Álvaro Cunqueiro Hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudia Barca Díez | Galicia Sur Health Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Complex of Vigo | Vigo | Pontevedra | 36312 | Spain |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 11, 2026 | |
| Reset | Jul 7, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 11, 2026 | Jul 7, 2026 |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D055948 | Sarcopenia |
| D044342 | Malnutrition |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Body weight | Body weight measured in kilograms (kg). The tools used for anthropometric data collection included a weighing scale with an integrated stadiometer (Asimed® brand, manufactured by Sibelmed, Barcelona, Spain) and an anthropometric measuring tape. | Day 0, During the consultation |
| Height | Height measured in meters (m). The tools used for anthropometric data collection included a weighing scale with an integrated stadiometer (Asimed® brand, manufactured by Sibelmed, Barcelona, Spain) and an anthropometric measuring tape. | Day 0, During the consultation |
| Calf circumference | Calf circumference measured in centimeters (cm) at the point of maximum circumference. The tools used for anthropometric data collection included a weighing scale with an integrated stadiometer (Asimed® brand, manufactured by Sibelmed, Barcelona, Spain) and an anthropometric measuring tape. | Day 0, During the consultation |
| Body mass index (BMI) | Body mass index calculated as weight in kilograms divided by height in meters squared (kg/m²). | Day 0, During the consultation |
| Usual body weight | Self-reported usual body weight prior to disease or treatment, measured in kilograms (kg). | Day 0, During the consultation |
| Weight loss during treatment | Percentage and absolute change in body weight from baseline during osimertinib treatment. It was calculated using the following formula: %WL = [(usual weight - current weight)/usual weight] × 100 | Day 0, During the consultation |
| Food intake recall | Dietary intake assessed 24-hour food recall, including total caloric and macronutrient intake. | Day 0, During the consultation |
| Fat mass (FM) by bioimpedance | Fat mass measured in kilograms using bioelectrical impedance analysis (BIA) the InBody S10® body composition analyzer (manufactured by InBody Co., Ltd., Seoul, Republic of Korea), was used, which is a device that measures impedance using 6 frequencies (1, 5, 50, 250, 500, and 1000 kHz) for each of the 5 body segments: right arm, left arm, trunk, right leg, and left leg. The measurements were performed with patients standing barefoot, with their legs apart and arms not touching the torso. The 8-point tactile electrodes were placed on the thumb and middle finger of each hand and on both ankles. The data obtained were analyzed using the LookinBody 120® software. | Day 0, During the consultation |
| Lean body mass (LBM) by bioimpedance | Lean body mass measured in kilograms using bioelectrical impedance analysis (BIA) the InBody S10® body composition analyzer (manufactured by InBody Co., Ltd., Seoul, Republic of Korea), was used, which is a device that measures impedance using 6 frequencies (1, 5, 50, 250, 500, and 1000 kHz) for each of the 5 body segments: right arm, left arm, trunk, right leg, and left leg. The measurements were performed with patients standing barefoot, with their legs apart and arms not touching the torso. The 8-point tactile electrodes were placed on the thumb and middle finger of each hand and on both ankles. The data obtained were analyzed using the LookinBody 120® software. | Day 0, During the consultation |
| Lean body mass index (LBMI) | Lean body mass index calculated as lean body mass divided by height squared (kg/m²). A reduced muscle mass was considered for LBMI < 17 kg/m2 in men and <15 kg/m2 in women. Using bioelectrical impedance analysis (BIA) the InBody S10® body composition analyzer (manufactured by InBody Co., Ltd., Seoul, Republic of Korea), was used, which is a device that measures impedance using 6 frequencies (1, 5, 50, 250, 500, and 1000 kHz) for each of the 5 body segments: right arm, left arm, trunk, right leg, and left leg. The measurements were performed with patients standing barefoot, with their legs apart and arms not touching the torso. The 8-point tactile electrodes were placed on the thumb and middle finger of each hand and on both ankles. The data obtained were analyzed using the LookinBody 120® software. | Day 0, During the consultation |
| Muscle functionality | Muscle functionality was assessed through hand grip strength using a hydraulic dynamometer (Jamar®, manufactured by Performance Health, Warrenville, IL, USA), providing the strength of the dominant arm (kg). Three measurements were taken with the subject seated and without arm support, with a 60 s rest between each measurement to prevent muscle fatigue. Dynapenia or reduced strength was considered if the value was <27 kg in men and <16 kg in women. | Day 0, During the consultation |
| Day 0, During the consultation |
| Sarcopenia detection and diagnosis | Applying the EWGSOP2 algorithm proposed by the European Working Group on Sarcopenia in Older People (EWGSOP). The screening was performed using the Strength, Assistance walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire, and a score of 4 or higher was considered to indicate a risk of sarcopenia. Muscle strength was determined by dynamometry, and BIA or CC assessed muscle mass. Patients with low muscle strength were classified as dynapenic; presarcopenia was diagnosed in patients showing reduced muscle mass and no significant decrease in muscle strength; finally, sarcopenia was diagnosed in patients who, in addition to low hand grip strength, also exhibited a reduction in muscle mass. | Day 0, During the consultation |
| Quality of Life of the patients | It was assessed using the EQ-5D scale, a standardized tool that measures five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Additionally, patients completed a visual Analog scale (VAS) ranging from 0 to 100, reflecting their general health status. | Day 0, During the consultation |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |